scholarly article | Q13442814 |
P819 | ADS bibcode | 2014PLoSO...993067K |
P356 | DOI | 10.1371/JOURNAL.PONE.0093067 |
P8608 | Fatcat ID | release_773ik5dxmzhx7byx3q3xclfa5e |
P932 | PMC publication ID | 3965523 |
P698 | PubMed publication ID | 24667836 |
P5875 | ResearchGate publication ID | 261103348 |
P50 | author | Andreas Ranft | Q59841400 |
P2093 | author name string | Elizabeth R Lawlor | |
Uta Dirksen | |||
Andreas Bräuninger | |||
Stefan Gattenlöhner | |||
Tilmann Spieker | |||
Heribert Jürgens | |||
Nicolas Dedy | |||
Bianca Karnuth | |||
P2860 | cites work | An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma | Q21198840 |
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours | Q24298221 | ||
Real-time quantification of microRNAs by stem-loop RT-PCR | Q24535510 | ||
Pro-tumorigenic effects of miR-31 loss in mesothelioma | Q24607181 | ||
Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers | Q24634248 | ||
A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis | Q24649156 | ||
Most mammalian mRNAs are conserved targets of microRNAs | Q24655061 | ||
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma | Q28239992 | ||
A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG | Q28252253 | ||
Causes and consequences of microRNA dysregulation in cancer | Q28258994 | ||
MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31 | Q28305980 | ||
Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. | Q31157886 | ||
Bone cancers | Q33278496 | ||
Modeling initiation of Ewing sarcoma in human neural crest cells | Q33894979 | ||
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial | Q50784397 | ||
The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors | Q51019815 | ||
EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. | Q53487773 | ||
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. | Q54158232 | ||
Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. | Q54797647 | ||
Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. | Q55239231 | ||
Risk of recurrence and survival after relapse in patients with Ewing sarcoma | Q83731173 | ||
Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells | Q33992270 | ||
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial | Q33994512 | ||
Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development | Q33997274 | ||
Mesenchymal stem cell features of Ewing tumors | Q34003979 | ||
EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. | Q34283431 | ||
Antagonism pattern detection between microRNA and target expression in Ewing's sarcoma | Q34358973 | ||
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation | Q34963463 | ||
MetastamiRs: non-coding MicroRNAs driving cancer invasion and metastasis | Q35795725 | ||
Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. | Q36440340 | ||
Recent advances in the molecular pathogenesis of Ewing's sarcoma | Q36562720 | ||
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. | Q36701142 | ||
Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis | Q37426806 | ||
Metastamirs: a stepping stone towards improved cancer management | Q37806613 | ||
A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs | Q38334606 | ||
Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma | Q38338166 | ||
Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. | Q39304020 | ||
A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma | Q39331421 | ||
miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells | Q39716224 | ||
Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells | Q39757723 | ||
Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma | Q45242163 | ||
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients | Q46359097 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | mesenchymal stem cell | Q1922379 |
P304 | page(s) | e93067 | |
P577 | publication date | 2014-03-25 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion | |
P478 | volume | 9 |
Q35652286 | A trans-ethnic genome-wide association study identifies gender-specific loci influencing pediatric aBMD and BMC at the distal radius. |
Q55663842 | Deep RNA sequencing reveals the dynamic regulation of miRNA, lncRNAs, and mRNAs in osteosarcoma tumorigenesis and pulmonary metastasis. |
Q60912671 | Defining a Characteristic Gene Expression Set Responsible for Cancer Stem Cell-Like Features in a Sub-Population of Ewing Sarcoma Cells CADO-ES1 |
Q38243325 | Effects of mesenchymal stromal cell-derived extracellular vesicles on tumor growth |
Q37116507 | Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy. |
Q35577760 | Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas |
Q38296481 | MicroRNA expression and its clinical implications in Ewing's sarcoma |
Q44848925 | MicroRNA-31 suppresses the self-renewal capability of α2δ1+ liver tumor-initiating cells by targeting ISL1. |
Q28087258 | MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics |
Q90733316 | Non-Coding RNAs in Pediatric Solid Tumors |
Q87621685 | Prognostic role of microRNA-31 in various cancers: a meta-analysis |
Q38446731 | Review of microRNA in osteosarcoma and chondrosarcoma |
Q26801785 | Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes |
Q38289575 | The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma |
Q35836010 | miR-599 Inhibits Vascular Smooth Muscle Cells Proliferation and Migration by Targeting TGFB2. |
Q38667026 | microRNA and Bone Cancer |
Search more.